Your browser doesn't support javascript.
loading
Association of obesity with disease outcome in multiple sclerosis.
Lutfullin, Isabel; Eveslage, Maria; Bittner, Stefan; Antony, Gisela; Flaskamp, Martina; Luessi, Felix; Salmen, Anke; Gisevius, Barbara; Klotz, Luisa; Korsukewitz, Catharina; Berthele, Achim; Groppa, Sergiu; Then Bergh, Florian; Wildemann, Brigitte; Bayas, Antonios; Tumani, Hayrettin; Meuth, Sven G; Trebst, Corinna; Zettl, Uwe K; Paul, Friedemann; Heesen, Christoph; Kuempfel, Tania; Gold, Ralf; Hemmer, Bernhard; Zipp, Frauke; Wiendl, Heinz; Lünemann, Jan D.
Afiliação
  • Lutfullin I; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Eveslage M; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
  • Bittner S; Department of Neurology, Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University, JGU, Mainz, Germany.
  • Antony G; Competence Network Parkinson's Disease, Central Information Office, Philipps-University Marburg, Marburg, Germany.
  • Flaskamp M; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, München, Germany.
  • Luessi F; Department of Neurology, Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University, JGU, Mainz, Germany.
  • Salmen A; Department of Neurology, St Josef-Hospital, Ruhr-Universitat Bochum, Bochum, Germany.
  • Gisevius B; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Klotz L; Department of Neurology, St Josef-Hospital, Ruhr-Universitat Bochum, Bochum, Germany.
  • Korsukewitz C; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Berthele A; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Groppa S; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, München, Germany.
  • Then Bergh F; Department of Neurology, Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University, JGU, Mainz, Germany.
  • Wildemann B; Clinic and Polyclinic for Neurology, University Hospital Leipzig, University Leipzig, UL, Leipzig, Germany.
  • Bayas A; Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
  • Tumani H; Department of Neurology, Faculty of Medicine, University of Augsburg, 86156, Augsburg, Germany.
  • Meuth SG; Department of Neurology, University of Ulm, Ulm, Germany.
  • Trebst C; Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Zettl UK; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Paul F; Division of Neuroimmunology, Department of Neurology, University Medicine Rostock Center of Neurology, Rostock, Germany.
  • Heesen C; NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, CHA, Berlin, Germany.
  • Kuempfel T; Department of Neurology, University Medical Center Hamburg-Eppendorf, UKE, Hamburg, Germany.
  • Gold R; Institute for Clinical Neuroimmunology, University Hospital und Centre for Biomedicine, Ludwig-Maximilians-University Munich, Munchen, Germany.
  • Hemmer B; Department of Neurology, St Josef-Hospital, Ruhr-Universitat Bochum, Bochum, Germany.
  • Zipp F; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, München, Germany.
  • Wiendl H; Department of Neurology, Technische Universitat Munchen and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Lünemann JD; Department of Neurology, Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University, JGU, Mainz, Germany.
J Neurol Neurosurg Psychiatry ; 94(1): 57-61, 2023 01.
Article em En | MEDLINE | ID: mdl-36319190
ABSTRACT

BACKGROUND:

Obesity reportedly increases the risk for developing multiple sclerosis (MS), but little is known about its association with disability accumulation.

METHODS:

This nationwide longitudinal cohort study included 1066 individuals with newly diagnosed MS from the German National MS cohort. Expanded Disability Status Scale (EDSS) scores, relapse rates, MRI findings and choice of immunotherapy were compared at baseline and at years 2, 4 and 6 between obese (body mass index, BMI ≥30 kg/m2) and non-obese (BMI <30 kg/m2) patients and correlated with individual BMI values.

RESULTS:

Presence of obesity at disease onset was associated with higher disability at baseline and at 2, 4 and 6 years of follow-up (p<0.001). Median time to reach EDSS 3 was 0.99 years for patients with BMI ≥30 kg/m2 and 1.46 years for non-obese patients. Risk to reach EDSS 3 over 6 years was significantly increased in patients with BMI ≥30 kg/m2 compared with patients with BMI <30 kg/m2 after adjustment for sex, age, smoking (HR 1.87; 95% CI 1.3 to 2.6; log-rank test p<0.001) and independent of disease-modifying therapies. Obesity was not significantly associated with higher relapse rates, increased number of contrast-enhancing MRI lesions or higher MRI T2 lesion burden over 6 years of follow-up.

CONCLUSIONS:

Obesity in newly diagnosed patients with MS is associated with higher disease severity and poorer outcome. Obesity management could improve clinical outcome of MS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article